ROCKaspire: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open-label extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation
This study will evaluate the efficacy and safety of belumosudil treatment in male or female
participants ≥18 years of age with CLAD Stages 1 or 2, at least 1 year post bilateral lung
transplantation.
Study details
Study-ID: 2023-503462-23-00
Study-ID: 2023-503462-23-00
DZL Disease Area: ROR, DPLD
DZL Disease Area: ROR, DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: CPC-M
DZL Participating Sites: CPC-M
Start Date: 01.12.2024
Completion Date: 01.06.2026
Status: Recruiting
Status: Recruiting
DZL recruiting center
Disease: adult participants with chronic lung allograft dysfunction (CLAD)
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
